Novartis Data Presented at ASCO Shows LBH589 Significantly Improved Progression-Free Survival in Patients with Multiple Myeloma
June 02, 2014 at 09:04 AM EDT
Novartis (NYSE: NVS) today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) ...
